What is Surgitech?
Surgitech Inc. operates at the intersection of medical engineering and clinical application, specializing in the research, development, and manufacturing of high-precision surgical technologies. The firm is best known for its flagship product, the Chronic Pain Suppressor CPS-2000, a sophisticated, prescription-controlled electro-stimulation device. By prioritizing rigorous compliance with federal medical standards and quality assurance protocols, Surgitech provides healthcare providers and patients with reliable, evidence-based alternatives for chronic pain management. Their commitment to regulatory excellence ensures that every device meets the stringent requirements necessary for widespread clinical adoption.
How much funding has Surgitech raised?
Surgitech has raised a total of $427K across 2 funding rounds:
Debt
$150K
Debt
$277K
Debt (2020): $150K with participation from PPP
Debt (2021): $277K led by PPP
Key Investors in Surgitech
PPP
Public-Private Partnership
What's next for Surgitech?
With the successful completion of this late-stage financing round, Surgitech is well-positioned to scale its manufacturing capabilities and expand its distribution network. The strategic deployment of this capital will likely focus on accelerating the commercialization of the CPS-2000 and investing in next-generation R&D to broaden their therapeutic portfolio. As the company transitions into this growth phase, the focus will remain on maintaining high-quality standards while capturing a larger share of the pain management market, ultimately driving long-term value for stakeholders and improving patient outcomes through technological advancement.
See full Surgitech company page
